First approved for adults in 2022, the therapy is now cleared for adults and pediatric patients weighing 66 lbs or more with symptomatic obstructive hypertrophic cardiomyopathy.
News|Articles|November 6, 2006
Here comes another parade of OTCs
Make room for yet another deluge of over-the-counter products. Here's a glimpse.
Advertisement
Oral care
Advertisement
Related to this article
The once daily tablet is expected to reach US patients in October 2026.
The label expansion adds patients 12 years of age and older to the once daily alopecia areata indication.
Advertisement
Advertisement
Trending on Drug Topics
1
From Binder to Action: Making Infectious Disease Outbreak Plans Operational
2
Retatrutide Delivers 20.8% Weight Loss in Adults With Type 2 Diabetes
3
Diabetes Medication Adherence Lags for Black and Hispanic Medicare Patients
4
FAQ: Policies for Pharmacists to Track Heading into 2026 Midterms
5